Title
Category
Credits
Event date
Cost
Skin of Color Symposium: Dermatology Pearls for Treating Pediatric Patients of Color
  • LivDerm
  • TME
  • 1.75 AAPA Category I CME
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 ANCC
  • 1.75 Participation
$0.00
Pediatric patients with melanin-rich skin, or skin of color (SOC), can be disproportionately affected by numerous dermatologic conditions. Patients can be more susceptible or have a greater disease burden, especially with conditions such as acne, atopic dermatitis, psoriasis, pigmentary disorders, and hair disorders.
Clinical Brief: IL-13 inhibitors: Advances and Considerations for Managing Moderate-to-Severe Atopic Dermatitis
  • LivDerm
  • TME
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 ANCC
  • 0.25 Participation
$0.00
Timely and adequate treatment of atopic dermatitis (AD) is essential for helping to promote better long-term outcomes and quality of life and may help prevent the development of other atopic conditions.
Primer: Gamechangers in Alopecia Areata: Targeted Therapies for Patient-Centered Care
  • LivDerm
  • TME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Currently, the standard of care for patients with alopecia areata (AA) is insufficient, challenging clinicians to find effective treatments in practice. Recent findings have furthered understanding of AA, including the targeting of specific immunologic pathways, which has led to the development of Janus kinase (JAK) inhibitors as an emerging therapeutic option. Additionally, studies have uncovered risk factors for AA that clinicians need to be aware of when treating either pediatric or adult patients. 
Atopic Dermatitis Summit: Perspectives on a Global Burden of Disease
  • LivDerm
  • TME
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
$0.00
The treatment of AD is a clinical challenge on a global level. Targeted immunomodulatory agents, based on recent advances in the understanding of the disease pathophysiology, represent additional options for long-term control.
Gamechangers in Alopecia Areata: Targeted Therapies for Patient-Centered Care
  • LivDerm
  • TME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Currently, the standard of care for patients with alopecia areata (AA) is insufficient, challenging clinicians to find effective treatments in practice. Recent findings have furthered understanding of AA, including the targeting of specific immunologic pathways, which has led to the development and FDA-approval of Janus kinase (JAK) inhibitors as an emerging therapeutic option. Moreover, these vital healthcare providers need education on disease pathophysiology, burden, and the impact this illness imparts on the whole patient.
Infants and Atopic Dermatitis: The Biggest Help for the Smallest Patients
  • LivDerm
  • TME
  • 1.00 AAPA Category I CME
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Pediatric patients with skin of color (SOC) face unique challenges in managing AD, including issues with disease associated sequelae. In fact, these patients are more likely to suffer from more severe AD cases. It has also been observed that patients with darker pigmented skin are more likely to develop hypo or hyperpigmentation at the affected sites of disease, and these effects often remain long after the symptoms have gone.
Timely Management of Moderate-to-Severe Hidradenitis Suppurativa: Addressing Barriers to Care for Patients in Need
  • LivDerm
  • TME
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
$0.00
Hidradenitis suppurativa (HS), also called acne inversa, is an inflammatory disease characterized by recurring, painful abscesses, and fistulous tracts, and can impact adults and pediatric patients. Symptoms of HS include pain and scarring as well as psychological consequences, such as embarrassment, social isolation, and depression, and is associated with a poor quality of life. Several studies suggest that the prevalence of HS ranges from 0.00033 to 4.1%, although underdiagnosis or improper diagnosis is an issue. 
Highlights of the 21st Annual South Beach Symposium 2023
  • LivDerm
  • TME
  • 2.00 AAPA Category I CME
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 ANCC
  • 2.00 Participation
$0.00
The ever-increasing impact of dermatologic conditions continues to be a major challenge for dermatologists and other health care providers in the United States (US). Dermatology practitioners diagnose and treat more than 3000 diseases across the age spectrum.  Therefore, clinicians are challenged to remain current in their knowledge and competence in the diagnosis and management of cutaneous disease.  
A New Age in Pediatric Psoriasis: Case-Based Learning for Inclusive Care
  • LivDerm
  • TME
  • 1.00 AAPA Category I CME
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Psoriasis is an immune-mediated disease that currently affects more than 8 million Americans and 125 million people worldwide according to the World Psoriasis Day consortium. Symptoms of this disease are characterized by inflammation, commonly presenting as raised plaques and scales on the skin resulting from an overactive immune system.
Hidradenitis Suppurativa Clinician-Patient Summit
  • LivDerm
  • TME
  • 2.00 ACPE Pharmacy
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 ANCC
  • 2.00 Participation
$0.00
Hidradenitis suppurativa has significant impacts on patients’ quality of life, however, it remains underdiagnosed, misdiagnosed, or incorrectly treated.  Until recently, there was a scarcity of evidence about long-term management strategies and no evidence-based consensus guidelines.  The updated North American guidelines, as well as the growing armamentarium of agents in advanced clinical development, provide additional guidance for optimizing diagnosis and treatment of HS patients.  However, questions still remain about how to best individualize therapy and work as a partner with patients

Pages